Florent

Quick links to important sections

Florent

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Florent

Quick Facts

Property Description
Active ingredient Saccharomyces boulardii (CNCM I-745 strain)
Form Oral capsule or powder for reconstitution (sachet)
Pharmacological class Probiotic, Antidiarrheal (functional classification)
Origin Biological/Natural (specific yeast strain)
Manufacturer Biocodex (French pharmaceutical company)
Patient Group Adults and Children (various formulations available)

What is the Classification of Florent?

Florent is defined as an oral biotherapeutic agent, distinguishing it from traditional drugs that rely on synthesized chemical compounds. It is classified under the probiotic pharmacological class, with the active ingredient, Saccharomyces boulardii, assigned the ATC code A07FA02 by the World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. The efficacy of this single-strain yeast preparation for the supportive management of various gastrointestinal disturbances is clinically recognized and supported by pharmacological studies. This confirms that the medicine acts to stabilize and support the gut's natural defense mechanisms.


Composition: Florent’s Active Ingredient and Origin

The sole active ingredient in Florent is Saccharomyces boulardii, specifically the well-characterized and proprietary CNCM I-745 strain. This single-strain product has a biological/natural origin, having been historically isolated from the peels of tropical fruits. The product is manufactured by the French pharmaceutical company Biocodex, which has developed the lyophilized (freeze-dried) yeast strain for over 70 years. This proprietary strain is distinguished because it possesses unique properties, such as viability over a wide pH range and optimal growth at body temperature, that enable it to survive and reach the intestines. Florent is administered via the oral route as a capsule or a powder packaged in a sachet.


What is Florent’s General Purpose?

The overall purpose of Florent is the restoration and modulation of the intestinal flora to maintain a healthy digestive state. The Saccharomyces boulardii yeast works transiently in the gut to promote microbial balance and strengthen the integrity of the intestinal lining, or mucosal barrier. This action helps to suppress the growth of certain detrimental bacteria and their toxins. This core benefit makes it a choice often associated with maintaining digestive comfort, particularly when the gut flora faces temporary disruption. The functional benefit is supported by evidence that the strain positively influences the bacterial gut microbiota after disruption.

What side effects are possible with Florent?

Adverse Reaction Scope

The safety profile for Florent (Fluticasone Propionate HFA) lists adverse reactions categorized by frequency and the body system affected, based on official regulatory documents (EMA/FDA).

Adverse Reaction Category Examples of Documented Side Effects
Common (>3% Incidence) Upper respiratory tract infection, headache, throat irritation, dysphonia (hoarseness), candidiasis (thrush) of the mouth/pharynx, sinusitis, cough, bronchitis.
Serious/Clinically Significant Paradoxical bronchospasm, immediate hypersensitivity reactions (including anaphylaxis), adrenal suppression (hypercorticism), decreased bone mineral density, ocular effects (glaucoma, cataracts).
System-Organ Classes Infections, Nervous System, Respiratory/Thoracic, Endocrine, Immune System, Musculoskeletal.

Safety-Related Restrictions and Considerations

Limitations and Contraindications

  • Florent is contraindicated for the primary treatment of acute episodes of asthma, such as status asthmaticus, where intensive measures are required.
  • It should be used with caution in patients with existing active or quiescent infections, such as tuberculosis, systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex, due to the drug's immunosuppressive potential.

Population-Specific and Exposure Patterns

  • Pediatrics: Growth velocity must be monitored; potential for systemic effects (e.g., adrenal suppression) is noted.
  • Long-Term/High Dose Use: The risk of systemic effects, including reduction in bone mineral density (osteoporosis) and ocular changes (glaucoma/cataracts), is associated with high dosages or prolonged use.
  • Monitoring Notes: Regulatory labels require periodic monitoring for the development of oral candidiasis (thrush) and specific monitoring for reduced bone mass and ocular effects in at-risk patients.

Regulatory Safety Summary

The official safety information structures the overall risk profile by defining events by frequency, severity, and body system, and formalizes the management of systemic risks through required monitoring. The profile explicitly lists rare, serious events (e.g., paradoxical bronchospasm) that necessitate immediate discontinuation, while clearly stating limitations (e.g., not for acute attacks) to prevent severe outcomes documented in the regulatory data.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on official regulatory documents concerning potential overdose situations with Florent (fluticasone propionate).

Documented Overdose Profile

Overdose Context Clinical Manifestations/Symptoms
Acute Overdose (inhaled form) Generally not expected to produce life-threatening symptoms.
Chronic Overdose or Very High Dosages Signs of hypercorticism (Cushing’s Syndrome) and/or adrenal suppression (HPA-axis suppression) may occur.
Susceptible Individuals May experience adrenal suppression even at the regular prescribed dosage.

Emergency Actions and Required Medical Attention

In the event that symptoms of hypercorticism and/or adrenal suppression are observed, the official guidance requires that the drug should be discontinued slowly under medical supervision. Abrupt discontinuation of a corticosteroid may pose risk to the patient.

Due to the risks associated with chronic high exposure, patients who may be exposed to very high dosages or for long periods should be monitored for signs of hypercorticism and HPA-axis suppression.

While acute overdose with the inhaled product is not expected to be life-threatening, any instance of suspected overdose or the manifestation of severe symptoms should be immediately reported to a healthcare professional or Poison Control Center for guidance.

Therapeutic Uses of Florent

Quick Facts About Florent

  • Primary Use: Maintenance treatment for asthma.
  • Therapeutic Role: May help prevent asthma symptoms, such as wheezing and shortness of breath.
  • Important Note: It is a controller medication and is not for immediate relief of acute asthma symptoms.

Florent (a brand name for fluticasone) is a medication utilized for the long-term management of asthma in adult and pediatric patients (typically aged 4 and older, depending on the formulation). Its primary therapeutic purpose is to serve as prophylactic therapy, meaning it is intended to help prevent the onset of asthma symptoms over time when used regularly.

This medication is a component of a comprehensive care plan, which may also include a short-acting beta-agonist for immediate relief of sudden symptoms. For individuals with asthma, Florent may help manage the chronic inflammation of the airways that contributes to breathing difficulties. It may also be considered for patients who have required oral corticosteroid therapy to help reduce their reliance on such medications. It is important to note that Florent does not provide relief during an acute asthma attack and should be used exactly as prescribed by a healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Florent?

Eligibility for Florent (Saccharomyces boulardii CNCM I-745) is defined by official regulatory bodies, primarily through strict population exclusions to mitigate the risk of systemic fungal infection (fungemia).


Contraindications and Restrictions

Classification Population/Condition Restriction Basis
Absolute Contraindication Patients with a central venous catheter (central line) High, documented risk of life-threatening fungemia.
Absolute Contraindication Patients with a known yeast allergy Risk of allergic reaction/hypersensitivity.
Contraindication Critically ill or severely immunocompromised patients Elevated risk of systemic infection/fungemia.

Age and Physiological Eligibility

Florent is generally permitted for use in adults and children. However, use in specific populations is subject to caution or is not recommended due to a lack of established safety data:

  • Pregnancy and Lactation: Use is not recommended. Safety has not been definitively established for the developing fetus or breastfed infant due to insufficient reliable human data.
  • Infants and Older Adults: Caution is specifically advised for very small premature infants and the elderly who may have an increased risk profile for systemic infection.

What should I know about interactions with other medicines?

Florent Interactions with other medicines and products

Official regulatory documents describe distinct interaction profiles depending on the active ingredient of the product named Florent.

Fluticasone (Corticosteroid) Interactions

The primary documented interaction for Fluticasone involves substances that are potent inhibitors of the CYP3A4 enzyme, which is responsible for the drug’s metabolic clearance. Co-administration with Ritonavir is generally not recommended due to the significant risk of increased systemic exposure to Fluticasone. Other strong CYP3A4 inhibitors, such as Ketoconazole, may also increase plasma concentrations. Population-specific cautions note that patients with moderate to severe hepatic impairment may experience reduced clearance, which can compound interaction risks.

Saccharomyces boulardii (Probiotic Yeast) Interactions

For the probiotic yeast strain, the official profile is centered on maintaining the organism’s viability. Co-administration with antifungal agents (systemic or oral) is documented as potentially resulting in a loss of efficacy due to the antagonistic action against the yeast. Additionally, regulatory guidance suggests a minimum time separation of 2 to 3 hours between administration of Saccharomyces boulardii and antibacterial agents. A severe context-specific constraint exists for immunocompromised patients, where use is associated with a reported risk of fungemia.

Mechanism of Action

The action of Florent (Saccharomyces boulardii CNCM I-745) is localized to the gastrointestinal tract and involves three simultaneous mechanistic domains: toxin neutralization, trophic support, and immune modulation.


Toxin Neutralization and Anti-Secretory Action

This mechanism involves the yeast secreting a serine protease that directly degrades bacterial toxins (e.g., C. difficile toxins) within the lumen. This biochemical counter-action, alongside the inhibition of the host's cAMP signaling pathway, modulates fluid transport, resulting in decreased net water and electrolyte movement into the intestinal lumen.


Intestinal Barrier and Trophic Modulation

The mechanism modulates intestinal barrier integrity by influencing the stability of tight junctions. Soluble factors like polyamines secreted by the yeast promote the maturation of enterocytes and inhibit signaling that causes the breakdown of tight junctions. This action is associated with increased expression of host brush-border enzymes and modulates paracellular permeability.


Local Immune and Inflammatory Modulation

The yeast modulates the localized immune response by interacting with GALT cells and inhibiting key inflammatory pathways (like NF-kappaB and MAPK). This mechanism involves the modulation of excessive immune signaling, resulting in reduced output of pro-inflammatory cytokines and contributing to local immune homeostasis within the mucosa.

Dosage and Administration Information

How Florent is Used: Official Administration Guidelines

Florent (Fluticasone Propionate Inhalation Aerosol) is intended exclusively for the long-term, prophylactic management of asthma and must not be used for the immediate relief of acute asthma symptoms. It functions as a controller medication requiring consistent daily use over time.


Approved Dosing and Frequency

Instruction Detail
Route of administration Oral Inhalation via Metered-Dose Inhaler (MDI).
Dosing schedule Administered twice daily (BID), ideally at intervals of approximately 12 hours.
Standard Dose Initial doses range from 88 mcg to 220 mcg twice daily, adjusted based on the patient's previous therapy.
Maximum Dose The maximum recommended adult dose is 440 mcg twice daily.

Procedural Administration Requirements

Official instructions detail specific steps for proper use. The MDI device must be shaken well before each use. It also requires priming—releasing four test sprays—before the first use or if the device has not been used for more than seven days. To minimize local effects, patients are instructed to rinse the mouth with water and spit out the water immediately after each inhalation session.

Use in Specific Groups

Florent is approved for use in children 4 years of age and older, with a typical starting dose of 44 mcg twice daily. If a dose is missed, it should not be compensated for; the patient should simply take the next scheduled dose at the regular time, maintaining the continuous twice daily pattern. Dosage adjustments for older adults or in cases of renal or hepatic impairment are generally not specifically mandated in the official prescribing documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Florent

The following is a summary of the research structure and the types of findings that have been reported for Florent (fluticasone propionate) in the context of asthma maintenance treatment. This information describes what has been studied for but does not provide individual medical advice or make claims about personal outcomes.

Evidence for use in Asthma Maintenance Treatment

Florent was studied for the management of persistent asthma in a number of controlled clinical trials, including randomized studies. These studies generally included adult and adolescent patients, and sometimes involved participants who were already using bronchodilators or other inhaled medications. Researchers examined outcomes related to physiological strain, such as changes in lung function measurements like FEV1 and PEF, over short-term periods, typically 12 weeks. They also monitored outcomes describing episodic or acute changes, such as the reported frequency of asthma worsening events (exacerbations) and how often patients used their short-acting rescue inhalers. Findings describe patterns observed in the studies over the defined treatment periods, primarily reporting the measured changes in lung function and the recorded frequency of exacerbations and rescue medication use in the groups included in the trials.

Comparing Florent to Other Treatment Types

Research has also evaluated Florent in settings designed to compare its recorded effects against a non-medicated dummy treatment (placebo) or against other active medications used in research exploring how symptoms change over time for asthma. In studies comparing Florent to a placebo, findings describe measurements related to lung function and rescue medication use during the study period. In some comparison studies, research described patterns that varied across measured endpoints.

Long-Term Studies and Follow-Up Data

Research has explored the long-term patterns associated with Florent use beyond the standard short-term trial duration. However, long-term effects are not fully established, and follow-up durations were limited in many of the controlled trials. There is limited information for long-term outcomes regarding the absolute continuation of observed measurements.

Evidence in Special Populations

Specific research has examined the use of Florent in certain special populations, including younger children and older adults. Florent was observed in children aged 4 years and older in some studies, which also monitored measurements related to growth velocity, which was studied for in children and adolescents. The evidence suggests that the patterns of observed measurements in older adults were generally similar to those found in younger adult participants. Limited information is available for long-term outcomes in patients with significant co-existing conditions, particularly severe hepatic or renal impairment.

Evidence Gaps and Areas for Future Research

Although many clinical trials have been conducted, evidence quality varies across studies, and certain uncertainties remain regarding the use of Florent. Overall, the research contributes to the broader evidence landscape, and the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Florent (FAQ)

Q: How quickly does Florent start working?

A: Fluticasone (inhalation product) is intended for long-term preventive management and is not a treatment for acute, sudden breathing problems. Studies indicate that the full benefit on measured lung function from consistent daily use may take up to two weeks to be observed in patient populations. The Saccharomyces boulardii product typically begins its action locally in the gut shortly after administration.

Q: Is it normal to feel tired after starting Florent?

A: Official product information for Fluticasone does not list general tiredness or fatigue among the most common adverse reactions. However, feeling tired or weak has been reported as a symptom associated with potential systemic effects from inhaled corticosteroids. Regulatory documents mention this type of symptom as associated with potential systemic effects from inhaled corticosteroids.

Q: Why did my doctor prescribe Florent instead of another drug?

A: Official research has compared the effects of Florent (Fluticasone) to both a non-medicated placebo and other active medications used for the condition. The findings describe patterns related to measured clinical endpoints that varied across different study groups. Regulatory documents describe what has been studied but do not advise on individual prescribing decisions.

Q: Does Florent cause weight gain or loss?

A: Weight changes are not listed among the common side effects for Fluticasone. However, symptoms such as weight gain around the upper back or abdomen have been reported as a sign of potential systemic effects (like Cushing’s syndrome) associated with long-term, high-dose use of inhaled corticosteroids. Official product information notes this as a potential finding that may be tracked.

Q: Can I take Florent if I have kidney problems?

A: For Fluticasone, official documentation notes that dosage adjustments for issues with renal (kidney) function are generally not specifically mandated. For the Saccharomyces boulardii product, specific restrictions related to kidney function are not detailed in official documentation.

Q: Is anxiety a known side effect of Florent?

A: While not a common side effect, mental or mood changes, which may include anxiety, have been reported as a potential symptom associated with the systemic effects of Fluticasone (inhaled corticosteroid). This is a finding that has been reported and noted in the official product profile.

Q: What happens if I stop taking Florent suddenly?

A: Fluticasone is a long-term controller medication. Official guidance indicates that Fluticasone should not be stopped suddenly without appropriate professional oversight. Abrupt cessation of long-term use can lead to the return or worsening of breathing symptoms and carries a risk due to the potential for adrenal suppression (where the body stops producing enough natural hormones).

Q: Can I take over-the-counter pain relievers while on Florent?

A: Official regulatory documents list only potent CYP3A4 inhibitors and certain other steroids as having known interactions with Fluticasone. The regulatory documents do not list common over-the-counter pain relievers as having known interactions with either product.

Q: Does Florent affect sleep patterns?

A: Sleep problems have been reported as an adverse reaction in some patients using Fluticasone inhalation products.

Q: Can Florent cause stomach upset?

A: For the Fluticasone inhaler, side effects such as nausea, vomiting, and diarrhea have been reported. The Saccharomyces boulardii product, while intended to support the gut, does not commonly list stomach upset as a side effect in its regulatory documentation.

Q: How soon after stopping Florent can I start another medication?

A: Fluticasone propionate is eliminated from the body via high clearance and shows a rapid initial elimination phase, followed by a prolonged terminal half-life of up to approximately 28 hours. This rapid clearance followed by a prolonged half-life describes the drug's elimination from the body.

Q: What is the difference between Florent and older treatments for this condition?

A: Official research comparing Fluticasone to older treatments, such as oral steroids, describes a difference in where the drug acts. Fluticasone exerts its anti-inflammatory effects locally in the airways, which is typically associated with fewer systemic effects throughout the body compared to older oral steroid treatments.

Q: Is Florent a type of antibiotic?

A: No. Florent is classified either as an inhaled corticosteroid (Fluticasone) for respiratory conditions or as an oral biotherapeutic agent/probiotic (Saccharomyces boulardii) for the gastrointestinal tract. Neither of these classifications defines the product as an antibiotic.

Q: Can Florent affect my ability to drive?

A: Fluticasone products generally do not list driving impairment as a primary concern. The product information for Fluticasone generally notes that if effects like drowsiness (somnolence) are experienced, caution is recommended regarding activities that require complete mental alertness.

Q: Is Florent safe to use during pregnancy?

A: For Fluticasone, official sources classify it based on animal studies that showed adverse effects but with no demonstrated risk in human studies. However, the use of Saccharomyces boulardii is not recommended during pregnancy or lactation due to insufficient reliable human data to establish safety for the developing child.

Q: Is there a generic version of Florent available?

A: The active ingredient in Florent (Fluticasone Propionate MDI) is available in FDA-approved authorized generic versions in various strengths. Similarly, the active ingredient Saccharomyces boulardii is available under a number of different brands and product names.

Q: Is Florent used to treat other conditions besides the main one?

A: Official regulatory approvals show that Fluticasone Propionate is used in different dosage forms. In addition to being an inhaled asthma treatment, it is approved for use as a topical cream or ointment for inflammatory skin conditions and as a nasal spray for allergic rhinitis.

Q: Is there a specific time of day that is best to take Florent?

A: Fluticasone is prescribed to be taken twice a day, and official instructions recommend taking the doses at intervals of approximately 12 hours. Consistent use, maintaining regularly spaced doses every day, is described as necessary for the desired preventive action.

Q: What are some common misunderstandings about Florent?

A: A key clarification in official documents is that Fluticasone is not a rescue medication. The regulatory labeling explicitly states that it is contraindicated for the primary treatment of acute, sudden asthma episodes and is only intended for long-term, preventive management.

Q: Can I be allergic to Florent?

A: Yes, regulatory information notes the potential for immediate hypersensitivity reactions (including anaphylaxis) with Fluticasone. For the Saccharomyces boulardii product, a known yeast allergy is listed as an absolute contraindication, meaning it should not be used by individuals with this allergy.

Q: Is it possible to become dependent on Florent?

A: Official sources do not suggest dependence on either product. The Saccharomyces boulardii product is a transient yeast, and research indicates it is typically no longer found in stools a few days after the product is stopped. For Fluticasone, the concern is not dependence but the potential for adrenal suppression (hormonal imbalance) with long-term, high-dose use.

Q: What does official guidance say about stopping Florent?

A: Official guidance indicates that Fluticasone should not be stopped suddenly. If discontinuation is considered, official guidance recommends oversight and often involves a gradual dosage reduction to help the body adjust and to manage the return of symptoms.

Q: Can Florent cause changes in mood?

A: Yes, mood changes, including depression, mood swings, or agitation, have been listed among the reported adverse reactions associated with the systemic effects of Fluticasone (inhaled corticosteroid). This is a documented risk noted in the official product profile.

Q: What is the expected experience when first starting Florent?

A: As a preventive treatment, Fluticasone is not expected to provide immediate relief. Commonly reported effects when starting include minor adverse reactions such as headache, sore throat, or throat irritation. Since it is a preventive medication, the effects are gradual and not acute.

Q: Does taking Florent with food change how it works?

A: Fluticasone is designed to act locally in the lung, and the small amount that is swallowed has a negligible systemic effect. The Saccharomyces boulardii is generally stable and its local action in the gut is typically not significantly altered by being taken with food.

How should Florent be stored and disposed of?

How to Store and Dispose of Florent (Fluticasone) Inhaler

The Florent inhaler must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must not be frozen or refrigerated and must be protected from heat exceeding 49 C (120 F). It is essential to keep the canister in its original packaging and to store it out of the sight and reach of children.

Stability and Disposal

The inhaler must be discarded after the dose counter reaches zero or 2 months after opening the foil pouch, whichever comes first. Due to the canister's pressurized contents, it must not be punctured, thrown into a fire, or incinerated. Unused or expired medication should be disposed of via a local drug take-back program or according to local waste management regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Florent found in:

A-Z Index: